

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review

https://marketpublishers.com/r/MAD27D90DA1EN.html

Date: September 2021 Pages: 59 Price: US\$ 125.00 (Single User License) ID: MAD27D90DA1EN

Abstracts

Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.



Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Myriad Genetics Inc (Myriad) is a specialty molecular diagnostic company, which discovers and commercializes molecular diagnostic tests, and personalized medicine, and provides pharmaceutical and clinical services for major diseases. The company's product portfolio includes molecular diagnostic testing products that analyze genes, genetic expressions and corresponding proteins to assess a person's risk for developing diseases later in life; products related to diagnosis of disease; and determine a patient's likelihood of responding to a particular drug. Myriad markets its products through sales force in Europe and Canada and distributor agreements in countries in Latin America, Middle East, Asia and Africa. The company has operations in the US, Spain, France, Switzerland, the UK, Canada, Italy, Germany, Japan, Australia and the Netherlands. Myriad is headquartered in Salt Lake City, Utah, the US.

Myriad Genetics Inc Key Recent Developments

Aug 03,2021: Myriad Genetics delivers strong revenue and earnings growth in June 2021 quarter, continues to execute on strategic growth & transformation plans Jul 28,2021: Myriad Genetics Announces that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021 Jul 22,2021: Myriad Genetics supports new ACMG recommendation statement on



increasing access to carrier screening for all ethnicities

Jun 16,2021: Thomas P. Slavin, M.D., named Chief Medical Officer for Myriad Genetics May 20,2021: Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.



Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contents

SECTION 1 - ABOUT THE COMPANY

Myriad Genetics Inc - Key Facts Myriad Genetics Inc - Key Employees Myriad Genetics Inc - Key Employee Biographies Myriad Genetics Inc - Major Products and Services Myriad Genetics Inc - History Myriad Genetics Inc - Company Statement Myriad Genetics Inc - Locations And Subsidiaries Head Office Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview Myriad Genetics Inc - Business Description Product Category: Molecular Diagnostic Revenues Performance Product Category: Pharmaceutical and Clinical Service Revenues Performance Product Category: Diagnostics Segment Overview Performance Product Category: Other Segment Overview Performance **R&D** Overview Myriad Genetics Inc - Corporate Strategy Myriad Genetics Inc - SWOT Analysis SWOT Analysis - Overview Myriad Genetics Inc - Strengths Myriad Genetics Inc - Weaknesses Myriad Genetics Inc - Opportunities Myriad Genetics Inc - Threats Myriad Genetics Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS



Financial Ratios - Capital Market Ratios Financial Ratios - Annual Ratios Performance Chart Financial Performance Financial Ratios - Interim Ratios Financial Ratios - Ratio Charts

SECTION 4 – COMPANY'S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Myriad Genetics Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021 Myriad Genetics Inc, Medical Equipment, Deals By Type, 2015 to YTD 2021 Myriad Genetics Inc, Recent Deals Summary

SECTION 5 – COMPANY'S RECENT DEVELOPMENTS

Aug 03, 2021: Myriad Genetics delivers strong revenue and earnings growth in June 2021 quarter, continues to execute on strategic growth & transformation plans Jul 28, 2021: Myriad Genetics Announces that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021 Jul 22, 2021: Myriad Genetics supports new ACMG recommendation statement on increasing access to carrier screening for all ethnicities Jun 16, 2021: Thomas P. Slavin, M.D., named Chief Medical Officer for Myriad Genetics May 20, 2021: Myriad Genetics Appoints Melissa Gonzales to Lead Women's Health Business May 04, 2021: Labcorp to acquire Myriad's Vectra testing business for \$150m May 03, 2021: Myriad Genetics to update progress on transformation plan and growth initiatives, share long-term financial outlook at 2021 investor day Mar 29, 2021: Myriad Genetics announces Eric Santa as Chief Growth Officer, Names new diversity and marketing leaders Feb 23, 2021: Myriad Genetics delivers 6% sequential revenue growth; company

continues to execute strategic transformation plan Feb 16, 2021: Myriad Genetics to Announce December 2020 Quarterly Financial

Results on February 23, 2021

SECTION 6 – APPENDIX

Methodology Ratio Definitions



About GlobalData Contact Us Disclaimer





List Of Tables

LIST OF TABLES

Myriad Genetics Inc, Key Facts Myriad Genetics Inc, Key Employees Myriad Genetics Inc, Key Employee Biographies Myriad Genetics Inc, Major Products and Services Myriad Genetics Inc, History Myriad Genetics Inc, Subsidiaries Myriad Genetics Inc, Key Competitors Myriad Genetics Inc, Ratios based on current share price Myriad Genetics Inc, Annual Ratios Myriad Genetics Inc, Annual Ratios (Cont...1) Myriad Genetics Inc, Annual Ratios (Cont...2) Myriad Genetics Inc, Interim Ratios Myriad Genetics Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021 Myriad Genetics Inc, Medical Equipment, Deals By Type, 2015 to YTD 2021 Myriad Genetics Inc, Recent Deals Summary **Currency Codes Capital Market Ratios** Equity Ratios **Profitability Ratios** Cost Ratios Liquidity Ratios Leverage Ratios **Efficiency Ratios**



List Of Figures

LIST OF FIGURES

Myriad Genetics Inc, Performance Chart (2016 - 2020) Myriad Genetics Inc, Ratio Charts Myriad Genetics Inc, Medical Equipment, Deals By Year, 2015 to YTD 2021 Myriad Genetics Inc, Medical Equipment, Deals by Type, 2015 to YTD 2021



I would like to order

Product name: Myriad Genetics Inc (MYGN) - Financial and Strategic SWOT Analysis Review Product link: <u>https://marketpublishers.com/r/MAD27D90DA1EN.html</u>

Price: US\$ 125.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/MAD27D90DA1EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970